Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O15078

UPID:
CE290_HUMAN

ALTERNATIVE NAMES:
Bardet-Biedl syndrome 14 protein; Cancer/testis antigen 87; Nephrocystin-6; Tumor antigen se2-2

ALTERNATIVE UPACC:
O15078; Q1PSK5; Q66GS8; Q9H2G6; Q9H6Q7; Q9H8I0

BACKGROUND:
The Centrosomal protein of 290 kDa, recognized as Bardet-Biedl syndrome 14 protein, is integral to early and late steps of ciliogenesis. Its functions include facilitating the disappearance of centriolar satellites, transitioning primary ciliar vesicles to capped ciliary vesicles, and ensuring the proper localization of ciliary proteins.

THERAPEUTIC SIGNIFICANCE:
The protein's association with diseases such as Joubert syndrome 5 and Bardet-Biedl syndrome 14 highlights its therapeutic potential. Understanding its role could lead to breakthroughs in treating these genetic disorders by targeting the underlying mechanisms of ciliopathies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.